Memorial Sloan Kettering Cancer Center: Immunotherapy After Bladder Cancer Surgery May Reduce Recurrence, Study Shows
June 03, 2021
June 03, 2021
NEW YORK, June 3 (TNSJou) -- The Memorial Sloan Kettering Cancer Center issued the following news release on June 2, 2021:
New research from Memorial Sloan Kettering Cancer Center (MSK) medical oncologist Dean Bajorin, MD, and colleagues found that patients who received nivolumab (Opdivo(R)) after bladder cancer surgery reduced their overall risk for high-grade bladder cancer recurrence. This research was published today in the New England Journal of Medicine.
In this p . . .
New research from Memorial Sloan Kettering Cancer Center (MSK) medical oncologist Dean Bajorin, MD, and colleagues found that patients who received nivolumab (Opdivo(R)) after bladder cancer surgery reduced their overall risk for high-grade bladder cancer recurrence. This research was published today in the New England Journal of Medicine.
In this p . . .